Depomed Hot Flash Drug May Finally Be On Its Way To FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Despite the product’s rocky history, Depomed says it is ready to file its non-hormonal hot flash treatment Serada (extended-release gabapentin) based on a recent meeting with FDA. But a mixed Phase III dataset raises doubts about approvability.
You may also be interested in...
Three For III: Depomed Will Conduct Another Late-Stage Trial Of Gabapentin Hot Flash Remedy
Placebo response sunk two earlier Phase III studies for the proprietary slow-release gabapentin formulation.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.